TY - JOUR
T1 - The Unique Symptom Burden of Patients Receiving CAR T-Cell Therapy
AU - Whisenant, Meagan S.
AU - Srour, Samer A.
AU - Williams, Loretta A.
AU - Subbiah, Ishwariah
AU - Griffin, Donna
AU - Ponce, Darcy
AU - Kebriaei, Partow
AU - Neelapu, Sattva S.
AU - Shpall, Elizabeth
AU - Ahmed, Sairah
AU - Wang, Xin Shelley
N1 - Publisher Copyright:
© 2021 Elsevier Inc.
PY - 2021/12
Y1 - 2021/12
N2 - Objectives: There is little research on the patient experience of symptom burden from CAR T-cell therapy, and no validated measure specific to the symptoms of CAR T-cell therapy currently exists. The purpose of this study was to identify symptoms experienced and to determine the content domain for a patient-reported outcome (PRO) measuring symptom burden for patients who had received standard of care CAR T-cell therapy for advanced B-cell lymphoid malignancies. Data Sources: Semi-structured qualitative interviews were conducted with a sample of 21 patients who had received CAR T-cell therapy. Content analysis was used to define the symptom burden content domain. Conclusion: Sixty-two percent of patients were interviewed within 3 months of therapy; 81.0% experienced cytokine release syndrome and 28.6% experienced neurotoxicity. Content analysis found 31 symptoms related to disease and treatment. The most common disease-related symptom identified by patients was pain (43%). The most common symptoms identified by patients as related to CAR T-cell therapy included fatigue (tiredness) (62%), lack of appetite (29%), headache (29%), chills or feeling cold (24%), and feeling confused (24%). The qualitative analysis also confirmed that symptoms interfere with daily activities, work, walking, relationships with others, mood, and enjoyment of life. Implications for Nursing Practice: Patients who receive standard CAR T-cell therapy experience numerous symptoms related to disease and CAR T-cell therapy, including symptoms related to the T-cell infusion. Symptoms may result in interference with daily activities, relationships, treatment adherence, and mood. Oncology nurses should be aware of and assess symptom related to CAR T-cell therapy.
AB - Objectives: There is little research on the patient experience of symptom burden from CAR T-cell therapy, and no validated measure specific to the symptoms of CAR T-cell therapy currently exists. The purpose of this study was to identify symptoms experienced and to determine the content domain for a patient-reported outcome (PRO) measuring symptom burden for patients who had received standard of care CAR T-cell therapy for advanced B-cell lymphoid malignancies. Data Sources: Semi-structured qualitative interviews were conducted with a sample of 21 patients who had received CAR T-cell therapy. Content analysis was used to define the symptom burden content domain. Conclusion: Sixty-two percent of patients were interviewed within 3 months of therapy; 81.0% experienced cytokine release syndrome and 28.6% experienced neurotoxicity. Content analysis found 31 symptoms related to disease and treatment. The most common disease-related symptom identified by patients was pain (43%). The most common symptoms identified by patients as related to CAR T-cell therapy included fatigue (tiredness) (62%), lack of appetite (29%), headache (29%), chills or feeling cold (24%), and feeling confused (24%). The qualitative analysis also confirmed that symptoms interfere with daily activities, work, walking, relationships with others, mood, and enjoyment of life. Implications for Nursing Practice: Patients who receive standard CAR T-cell therapy experience numerous symptoms related to disease and CAR T-cell therapy, including symptoms related to the T-cell infusion. Symptoms may result in interference with daily activities, relationships, treatment adherence, and mood. Oncology nurses should be aware of and assess symptom related to CAR T-cell therapy.
KW - CAR T-cell therapy
KW - Cancer
KW - Hematological malignancies
KW - Patient-reported outcomes
KW - Quality of life
KW - Symptom burden
KW - Symptoms
UR - http://www.scopus.com/inward/record.url?scp=85116802515&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85116802515&partnerID=8YFLogxK
U2 - 10.1016/j.soncn.2021.151216
DO - 10.1016/j.soncn.2021.151216
M3 - Article
C2 - 34629213
AN - SCOPUS:85116802515
SN - 0749-2081
VL - 37
JO - Seminars in oncology nursing
JF - Seminars in oncology nursing
IS - 6
M1 - 151216
ER -